EPO Berlin-Buch

EPO Berlin-Buch is a Germany-based preclinical contract research organization focused on oncology and immuno-oncology drug development. Founded in 1997 as a spin-off from the Max Delbrück Center for Molecular Medicine, the company provides customized in vivo and in vitro preclinical services for biotech, pharma, and academic customers worldwide. Its core capabilities include large collections of patient-derived xenograft, cell line-derived xenograft, syngeneic, orthotopic, and humanized tumor models, along with pharmacology, histopathology, biomarker, radiopharmaceutical, and translational study support. EPO appears to operate as a service provider rather than a therapeutic product developer, so its value proposition is enabling clients to evaluate and de-risk novel anticancer agents before clinical development.